Dasatinib-Related Chylothorax

被引：20

作者：

Huang, Yen-Min ^{[1
,2
]}

Wang, Cheng-Hsu ^{[1
,3
]}

Huang, Jen-Seng ^{[1
]}

Yeh, Kun-Yun ^{[1
]}

Lai, Chien-Hong ^{[1
]}

Wu, Tsung-Han ^{[1
]}

Chang, Pei-Hung ^{[1
]}

Chang, Yueh-Shih ^{[1
]}

Lan, Yu-Jenq ^{[1
]}

机构：

[1] Chang Gung Mem Hosp, Clin Internal Med, Div Hematol Oncol, Keelung, Taiwan

[2] Chang Gung Mem Hosp, Clin Internal Med, Div Hematol, Linkou, Taiwan

[3] Chang Gung Univ, Fac Med, Sch Tradit Chinese Med, Taoyuan, Taiwan

来源：

TURKISH JOURNAL OF HEMATOLOGY | 2015年 / 32卷 / 01期

关键词：

Dasatinib; Chylothorax; Chronic myeloid leukemia; CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; PLEURAL EFFUSION; CHRONIC-PHASE; IMATINIB; FAILURE; DISEASE;

D O I：

10.4274/tjh.2012.0196

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Dasatinib is a potent second-generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The most common adverse event associated with dasatinib therapy is fluid retention, including pleural effusion. Dasatinib-related chylothorax has rarely been reported. The clinical manifestations, pathophysiology, management, and prognosis are not fully understood. Here we report a 40-year-old woman presenting with chylothorax following dasatinib use. We propose the hypothesis of its mechanism as well as offering a review of the relevant literature.

引用

页码：68 / 72

页数：5

共 50 条

[1] DASATINIB-RELATED CHYLOTHORAX
Young, Katherine
Formanek, Perry
Kumar, Sunita
CHEST, 2019, 156 (04) : 1208A - 1208A
[2] Successful Control of Dasatinib-related Chylothorax by the Japanese Herbal Medicine "Goreisan"
Sasaki, Hisashi
Kimizuka, Yoshifumi
Ogata, Hiraku
Okada, Yosuke
Ota, Shinichiro
Sano, Tomoya
Watanabe, Chie
Maki, Yohei
Yamamoto, Takayuki
Tagami, Yoichi
Miyata, Jun
Hayashi, Nobuyoshi
Fujikura, Yuji
Kawana, Akihiko
INTERNAL MEDICINE, 2019, 58 (21) : 3139 - 3141
[3] Dasatinib-related bleeding “mild and manageable”
Reactions Weekly, 2009, 1259 (1) : 5 - 5
[4] Dasatinib-related pneumonia? An example of pharmacovigilance survey
Audemard, A.
de la Gastine, B.
Chantepie, S.
Verger, H.
Gac, A. C.
Bergot, E.
Reman, O.
REVUE DES MALADIES RESPIRATOIRES, 2015, 32 (01) : 84 - 86
[5] Is dasatinib-related pulmonary hypertension a clinical concern?
Szmit, Sebastian
FUTURE ONCOLOGY, 2015, 11 (18) : 2491 - 2494
[6] Dasatinib-related alveolar pneumonia responsive to corticosteroids
Radaelli, F.
Bramanti, S.
Fantini, N. N.
Fabio, G.
Greco, I.
Lambertenghi-Deliliers, G.
LEUKEMIA & LYMPHOMA, 2006, 47 (06) : 1180 - 1181
[7] Dasatinib-Related Pulmonary Toxicity Mimicking an Atypical Infection
Jasielec, Jagoda K.
Larson, Richard A.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (06) : E46 - E48
[8] Dasatinib-related Follicular Hyperplasia An Underrecognized Entity With Characteristic Morphology
Ozawa, Michael G.
Ewalt, Mark D.
Gratzinger, Dita
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2015, 39 (10) : 1363 - 1369
[9] Reversible dasatinib-related pulmonary arterial hypertension diagnosed by noninvasive echocardiography
Wang, Hui-Ching
Lee, Chee-Siong
Liu, Ta-Chih
KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2015, 31 (03): : 165 - 166
[10] Dasatinib-related effusion lymphoma in a patient treated for chronic myeloid leukaemia
Miyagi, Daichi
Chen, Wei-Yu
Chen, Bo-Jung
Su, Ying-Zhen
Kuo, Chun-Chi
Karube, Kennosuke
Chuang, Shih-Sung
CYTOPATHOLOGY, 2020, 31 (06) : 602 - 606

← 1 2 3 4 5 →